19 july 2018 daily equity reports

1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 19THJULY 2018 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET CLOSE PREVIOUS ! 36373.44 INDIAN EQUITY BENCHMARK:- The Sensex ended lower by 146.52 points or 0.40% at 36373.44, while the Nifty was down 26.00 points or 0.24% at 10982.00. The market breadth was negative as 878 shares advanced, against a decline of 1,689 shares, while 149 shares are unchanged. Investors looked to cash out of majority of sectoral indices, with major cuts visible among metals, auto and FMCG names. Weakness among midcaps too weighed on the market. The Nifty Midcap index ended over 1 percent lower. ONGC, Asian Paints, and Indiabulls Housing were the top gainers on both indices, while metal stocks such as Tata Steel, Vedanta and Hindalco were the top losers. GLOBAL FACE 10980.45 ASIAN MARKET CLOSE PREVIOUS NIKKEI 22794.19 28117.42 2297.92 SECTORIAL INDICES CLOSE CHANGE (%) 11189.10 -0.37 -0.49 -1.66 ! Asian Market - Asian markets finished mixed as of the most recent closing prices. The Nikkei 225 gained 0.43%, while the Shanghai Composite led the Hang Seng lower. They fell 0.39% and 0.23% respectively. -0.45 26880.90 -0.47 ! CLOSE CHANGE (%) U.S. Market -U.S. Stocks Higher After Fed Chairman Jerome Powell's Testimony IBULHSGFIN 1999.05 4.03 ! 2.66 European markets - European markets are higher today with shares in Germany leading the region. The DAX is up 0.62% while London's FTSE 100 is up 0.57% and France's CAC 40 is up 0.47%. BPCL 2.25 1.78 TOP LOSERS CLOSE CHANGE (%) -5.33 -3.01 VEDL -2.95 UPL -2.54 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE STRATEGY SCRIPT CLOSE (%) 7.30 PIVOT POINTS P 11004 R1 R2 11124 RESISTANCE R1-11060 R2-11185 R3 11244 7.12 10764 10884 10932 11052 6.70 SUPPORT S1-10910 S2-10800 1997.30 6.41 TCS CLOSE (%) TATAGLOBAL BANK NIFTY FUTURE NET BULLISH (CR.) PIVOT POINTS P 27028 S3 S1 26824 R1 27171 R2 R3 4113.54 4787.53 26334 26681 RESISTANCE DII 3410.59 BANK NIFTY NSE TOTALS ADVANCE BANK NIFTY 4 8 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report MARKET TALKS ! ! Government approves Rs11,336cr capital infusion in five PSU Banks Ashok Leyland plunges more than 14% in intraday trade on truck axle loading concerns India’s largest pure play listed commercial vehicle (CV) maker, Ashok Leyland Limited (ALL) plunged more than 14% in intraday trade today owing to concerns surrounding axle loading norms. The Ministry of Road Transport and Highways recently notified norms allowing for higher loading of trucks and trailers. The Finance Rs11,336cr in Corporation Bank and Andhra Bank to help them meet regulatory capital requirements. The infusion would be part of remaining Rs65,000cr out of Rs 2.11 lakh cr capital infusion over two financial years. This is positive move for these state owned banks, and was due for this fiscal year. It shows the commitment of the government to improve the financial health of the state owned banks. The stocks to trade with positive bias today. Sun Pharma gets first approval from Halol facility post EIR Sun Pharmaceutical Industries announced that it has received final USFDA approval Infugem IV for intravenous use in a ready-to-administer (RTA) bag. This is the first USFDA product approval from Sun Pharma’s Halol facility after it recieved an Establishment Inspection Report (EIR) in June 2018. Ministry yesterday five state-owned approved infusion of lenders including PNB, ! Mylan signs agreement with AbbVie, will it be positive for Biocon? ! Mylan has announced that it has entered in a patent license agreement with AbbVie over Mylan’s proposed Humira biosimilar. As per the agreement, AbbVie will grant Mylan exclusive licences on Humira’s intellectual properties on July 31, 2023 in the United States and various other countries but excluding Europe. Humira (Adalimumab) is a biologic drug which is indicated in the treatment of rheumatoid arthritis and Crohn’s disease. Humira reported sales of $18.4bn in 2017 and is bestselling drug in the world at the moment. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. Capitalstars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market.we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors.we provide intraday as well as delivery stock tips in NSE and BSEand commodity tips in MCX and NCDEX. Visit us: www.capitalstars.com Call us: 9977499927 7440449744 Our services: Mcx Tips Intraday Stock Tips Finacial Advisory Company

7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.